Study of ADX-038 for geographic atrophy in dry AMD
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have geographic atrophy (GA) from dry age-related macular degeneration (AMD).
- The GA spot in your study eye should be between the size of a small freckle and a pencil eraser (2.5–12.5 mm²).
- You need to be willing to get meningococcal and pneumococcal vaccines before the trial starts.
- You should not have any other active eye disease that could affect your vision or the study results.
- You must not have had any other treatments for GA injected into your eye (like complement inhibitors).
- You should not have a history of retinal detachment surgery, active infections, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Hear when a new Geographic Atrophy Secondary to Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.